Atritech, Inc.

Covidien LP

Bacchus Vascular Inc.

Medtronic, Inc.

Tyco Healthcare Group LP

Ev3 Endovascular, Inc.

Ev3 Sunnyvale, Inc.

Artritech, Inc.

Dino De Cicco

Alexander K Khairkhahan

Michael D Lesh

Erik Van Der Burg

Chad C Roue

Andrew G C Frazier

Michael A Evans

Kelvin Ning

Tyler Jon Strang

Marc S Kriedler

Denise M Demarais

Marc S Kreidler

Alex K Khairkahan

Denise Marie Zarins

Stephen Arie Leeflang

Alex Khairkhahan

Edward V Kinney

Craig J Coombs

Deborah Tolomeo

Denise Demarias

Jody Maria Cimbalo

Alex K Khairkhahan

Disclosed is a method of preventing atrial appendage thrombus from entering the blood stream in which an occlusion device placed within the left atrial appendage inhibits compression of the left atrial appendage and facilitates tissue in-growth onto the occlusion member. The occlusion device includes an occlusion member, a plurality of supports and a plurality of barbs associated with the plurality of supports.

Method for left atrial appendage occlusion

Clot disruption and dissolution are achieved using a catheter having the ability to infuse a thrombolytic agent, aspirate clot and fluid, and allow passage of a guidewire. Optionally, the catheter may also include a mechanical agitator for further disrupt clot in the presence of the thrombolytic agent. A flow resistor in the catheter provides for infusion and/or aspiration to be concentrated primarily at a clot treatment area in a blood vessel while also providing optional infusion and/or aspiration distal to the treatment area. In some embodiments, infusion, aspiration and guidewire passage occur through a common lumen. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.

Apparatus and methods for clot dissolution

A device and method for obliterating or occluding a body cavity or passageway, in particular, the left atrial appendage of a patient's heart. The procedure can be carried out intraoperatively, but is preferably carried out percutaneously by use of a delivery catheter to position an occluding device adjacent a patient's left atrial appendage. The occluding device may prevent the passage of embolic or other material to or from the left atrial appendage by volumetrically filling the appendage, closing the opening of the appendage with an occluding member, or pulling the tissue around the opening of the appendage together and fixing it in a closed state.

Method and device for left atrial appendage occlusion

Disclosed is an occlusion device for use in a body lumen such as the left atrial appendage. The occlusion device includes a pumpable injectable material and a retention member having a tissue penetrating shaft which extends from a proximal end of the device to a distal end of the device.

An implantable device for containing emboli within an atrial appendage may include an expandable frame having a plurality of supports projecting distally from a proximal hub, a mesh barrier provided on proximal sections of the supports, and a plurality of tissue anchors provided on the supports for engaging tissue when the device is positioned in an atrial appendage.

Device for left atrial appendage occlusion

Disclosed is an occlusion device for use in a body lumen such as the left atrial appendage. The occlusion device includes an occlusion member and may also include a stabilizing member. The stabilizing member inhibits compression of the left atrial appendage, facilitating tissue in-growth onto the occlusion member. Methods are also disclosed.

Disclosed is an occlusion device for use in a body lumen such as the left atrial appendage. The occlusion device includes an occlusion member and a plurality of tissue retention structures. The tissue retention structures inhibits movement of the device from the left atrial appendage. Methods are also disclosed.

Device for containing embolic material in the LAA having a plurality of tissue retention structures

Clot disruption and dissolution are achieved using a catheter having the ability to infuse a thrombolytic agent, agitate the clot and agent, and aspirate broken-up clot from the blood vessel. A flow resistor in the catheter provides for infusion and/or aspiration to be concentrated primarily at a clot treatment area in a blood vessel while also providing optional infusion and/or aspiration distal to the treatment area. In some embodiments, infusion, aspiration and guidewire passage occur through a common lumen. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.

Methods, systems, and devices seal off the branch port of a bifurcated endoluminal prosthesis to transform the bifurcated prosthesis to a single-lumen prosthesis. These methods and devices are available for fallback procedures when the deployment of a bifurcated endoluminal prosthesis is found to be impracticable. By effectively sealing off the second branch port, the attending physician is able to completely isolate an aneurysm or other disease of the vasculature. Where it is necessary and/or desirable to provide fluid communication between the trunk lumen and the second branch lumen, a separate passage may be provided between the first and second branches of the body lumen system.

Endoluminal prosthetic bifurcation shunt

Growing community of inventors

Campbell, CA, United States of America

Dino De Cicco